RxSight, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 7, 2023 and accepted by EDGAR at Aug 7, 2023, 16:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $20.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $38.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $8.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $15.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $12.0m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $22.4m | us-gaap:GrossProfit |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $7.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $14.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $18.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $34.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$13.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$26.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $1.6m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $3.1m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $26.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $27.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$13.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$27.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$0.40 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$0.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.40 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$0.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 34,498,265 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 33,075,585 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$25.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $2.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $8.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $180.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $195.3m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $16.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $38.1m | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $19.6m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-06-30 | $157.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-039081. Last ingested by Listed: Nov 2, 2026, 19:48 ET. Listed shows no prices and gives no investment advice.